Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Qiong Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4830-9704; OpenAlex author ID A5100940452. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 9

  1. Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large-Scale Chinese Cohort. Co-author DOI 10.1002/cam4.72083↗
  2. Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.05.012↗
  3. Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer. Co-author DOI 10.1038/s41467-026-73702-z↗
  4. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Co-author DOI 10.1053/j.gastro.2025.03.019↗
  5. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  6. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  7. Identification of pancreatic adenocarcinoma immune subtype associated with tumor neoantigen from aberrant alternative splicing. Co-author DOI 10.21037/jgo-24-340↗
  8. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  9. Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in Pancreatic Adenocarcinoma: A Meta-Analysis. Co-author DOI 10.1177/1073274820977135↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 7 shared papers, 2023–2026 · strength 1.42
  2. Rong Tang · 5 shared papers, 2023–2026 · strength 1.08
  3. Si Shi · 5 shared papers, 2023–2026 · strength 0.99
  4. Jie Hua · 4 shared papers, 2023–2026 · strength 0.84
  5. Jin Xu · 4 shared papers, 2023–2026 · strength 0.79
  6. Zeyin Rong · 3 shared papers, 2025–2026 · strength 0.64
  7. Qingcai Meng · 3 shared papers, 2023–2025 · strength 0.57
  8. Chen Liang · 3 shared papers, 2023–2025 · strength 0.57
  9. Liquan Jin · 2 shared papers, 2026 · strength 0.46
  10. Zhen Tan · 2 shared papers, 2025 · strength 0.41
  11. Chenghao Shao · 2 shared papers, 2023–2026 · strength 0.38
  12. Wei Wang · 2 shared papers, 2023–2025 · strength 0.37
  13. Yuan Liu · 2 shared papers, 2023–2024 · strength 0.34
  14. Ying Liu · 1 shared paper, 2026 · strength 0.27
  15. Miaoyan Wei · 1 shared paper, 2026 · strength 0.27
  16. Mingwei Dong · 1 shared paper, 2026 · strength 0.27
  17. Xu Jk · 1 shared paper, 2026 · strength 0.27
  18. Xiao-Yu Yin · 1 shared paper, 2026 · strength 0.24
  19. Jiaoshun Chen · 1 shared paper, 2026 · strength 0.23
  20. Haoyu Wang · 1 shared paper, 2026 · strength 0.23
  21. Chen Chen · 1 shared paper, 2026 · strength 0.23
  22. Jianhui Yang · 1 shared paper, 2025 · strength 0.22
  23. Jiyong Liu · 1 shared paper, 2024 · strength 0.21
  24. Nicolas Jonckheere · 1 shared paper, 2024 · strength 0.21
  25. Bo Zhang · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.